Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Credits Available
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 3, 2022 Expiration: May 2, 2023
Start Activity
Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly
Allison Butts, PharmD, BCOP
Kristina F. Byers, PharmD, BCOP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss recent clinical evidence and the application of targeted oral therapies in personalized treatment planning for hormone receptor–positive/HER2-negative early and advanced breast cancer
  • Recognize and manage the adverse events associated with CDK4/6 and PI3K inhibitors, as well as novel SERD therapies
  • Integrate resources to engage patients in shared decision-making and medication adherence strategies for approved and investigational treatment options for hormone receptor–positive/HER2-negative early and advanced breast cancer

Information on this Educational Activity

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Allison Butts, PharmD, BCOP

Clinical Coordinator, Oncology Pharmacy
Director, PGY2 Oncology Residency Program
UK HealthCare
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has disclosed that she has received consulting fees from AstraZeneca and BeyondSpring.
Kristina F. Byers, PharmD, BCOP

Clinical Pharmacy Specialist
Breast Oncology
Emory Winship Cancer Institute
Atlanta, Georgia

Kristina F. Byers, PharmD, BCOP, has disclosed that she has received consulting fees from Seagen and has been a speaker for Wellstat Therapeutics.

Staff

Kelly Brandt, PharmD
Kelly Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Jamie Sebaaly

Director, Educational Strategy

Jamie Sebaaly has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The activity is intended for pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with hormone receptor–positive/HER2-negative early and advanced breast cancer, as well as other stakeholders in hematology/oncology practice.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of pharmacists in the management of patients with hormone receptor–positive/HER2-negative early and advanced breast cancer. 

Pharmacist Continuing Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-108-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 65% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 03, 2022, through May 02, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Loading...
Listen to the experts discuss current and emerging oral targeted therapies for advanced HR+/HER2- breast cancer, adverse event management, and strategies to promote adherence.
Allison Butts, PharmD, BCOP
Kristina F. Byers, PharmD, BCOP
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: May 3, 2022 Expiration: May 2, 2023

Related Content

Expert-selected slides on chronic lymphocytic leukemia with a pharmacy perspective to help treat your patients with CLL, from ProCE and Clinical Care Options (CCO).

Lydia Benitez, PharmD, BCOP Caitlin R. Rausch, PharmD Released: May 18, 2022

In slides from Clinical Care Options (CCO), expert pharmacists provide insights on the use of novel systemic therapies for HCC

Courtney C. Cavalieri, PharmD, BCOP Amber Draper, PharmD, BCOP Released: May 18, 2022

Commentary on advances in oral targeted therapies for the treatment of early and metastatic breast cancer, adverse event management, and tools for adherence, from Clinical Care Options (CCO)

Allison Butts, PharmD, BCOP Kristina F. Byers, PharmD, BCOP Released: April 25, 2022

Downloadable slideset from a HOPA satellite symposium developed by clinical pharmacy specialists with guidance on the management hematologic malignancies using CAR T-cell therapies.

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Released: April 1, 2022
Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings